The private company is focused on creating advanced treatments for ALS and other neurodegenerative diseases, using its patented macrophage-targeted technology, NP001, which addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received FDA Orphan Drug and Fast Track designation, and Neuvivo is committed to moving the compound towards approval to deliver an effective and safe new treatment for ALS.